Sign in

    Jim Molloy • Alliance Global Partners

    Jim Molloy is Managing Director and Senior Equity Research Analyst in Biotechnology & Specialty Pharmaceuticals at Alliance Global Partners, specializing in companies across immuno-oncology, central nervous system, cardiovascular, and anti-infective therapeutic areas. He covers mid-cap and emerging biotech names such as Tonix Pharmaceuticals, Soligenix, IGC Pharma, Intensity Therapeutics, and Oramed Pharmaceuticals, with data showing an average price target met ratio of 39.4%, average upside of 13.3%, and over 93% of ratings issued as 'Buy.' Molloy began his career at Leerink Partners and has held senior research roles at Oppenheimer, ThinkEquity Partners, Janney Montgomery Scott, Summer Street, and Laidlaw, joining Alliance Global Partners as Managing Director in 2018 after nearly two decades in healthcare equity research. He holds an MBA from Babson College, a BA from the University of Colorado Boulder, and maintains professional financial analyst credentials and FINRA securities licenses.

    Jim Molloy's questions to Talphera Inc (TLPH) leadership

    Jim Molloy's questions to Talphera Inc (TLPH) leadership • Q4 2024

    Question

    Speaking for Jim Molloy of Alliance Global Partners, an analyst asked for the expected timing of the private placement milestones, the strategy for optimizing underperforming clinical trial sites, and any early indications of the new enrollment rate.

    Answer

    CEO Vince Angotti projected the first financing milestone (17 patients) would be hit around mid-year and the second (35 patients) in the third quarter. Chief Medical Officer Dr. Shakil Aslam stated they are working with existing sites to shift PI responsibility to nephrologists and may deactivate unproductive sites as more high-potential sites come online. Vince Angotti added that while it's too early for a new enrollment rate, the potential patient pool is expanding exponentially with new sites that have 4-5 times more CRRT patients per month than the original sites.

    Ask Fintool Equity Research AI

    Jim Molloy's questions to Talphera Inc (TLPH) leadership • Q4 2024

    Question

    Asked for the expected timing of the private placement milestones, plans to optimize existing clinical sites by changing Principal Investigators (PIs), and the anticipated enrollment rate under the new study criteria.

    Answer

    The company expects to hit the first enrollment milestone (17 patients) around mid-year and the second (35 patients) in the third quarter. They are actively discussing shifting PIs at existing sites to nephrologists and may replace unproductive sites with more promising ones. While it's too early to give a precise new enrollment rate, they are confident it will accelerate significantly due to the protocol changes and the addition of new, larger sites with more CRRT patients.

    Ask Fintool Equity Research AI